News summary
[Zhongsheng Pharmaceutical: The wholly-owned subsidiary obtained the "Drug Registration Certificate" of Pralofen Eye Drops] Securities Times e Company Newsblackjackpoker, Zhongsheng Pharmaceutical (002317) announced on the evening of May 27 that its wholly-owned subsidiary Guangdong Huanan Pharmaceutical Group Co., Ltd. recently received approval from the State Food and Drug Administration.blackjackpoker...
Newsletter text
[Zhongsheng Pharmaceutical: The wholly-owned subsidiary obtained the "Drug Registration Certificate" of Pralofen Eye Drops] Securities Times e Company News, Zhongsheng Pharmaceutical (002317) announced on the evening of May 27 that its wholly-owned subsidiary Guangdong Huanan Pharmaceutical Group Co., Ltd. Recently received the "Drug Registration Certificate" of Pralofen Eye Drops approved and issued by the State Food and Drug Administration. The indication for pralofen eye drops is symptomatic treatment of inflammation of the external eye and anterior segment (blepharitis, conjunctivitis, keratitis, scleritis, superficial scleritis, iridocyclitis, postoperative inflammation).
